
Investors Face October Deadline in ARS Pharmaceuticals Fraud Lawsuit
Investors who purchased ARS Pharmaceuticals stock between March 9 and June 24, 2026, have until October 5 to move for lead plaintiff status in a pending securities class action. The lawsuit alleges the company misled shareholders regarding the insurance coverage timeline for its epinephrine nasal spray, neffy.


























